FINWIRES · TerminalLIVE
FINWIRES

$AVTX

7 stories mentioning AVTXUpdated 34d ago

Every FINWIRES story that references AVTX, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) marginally higher and the iShares Biotechnology ETF (IBB) down 0.1%.ACADIA Pharmaceuticals (ACAD) stock was up nearly 10% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.Incyte (INCY) shares were up 1.8% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Opzelura cream for adults with moderate atopic dermatitis.Avalo Therapeutics (AVTX) will be added to the small-cap Russell 2000 index and the broad-market Russell 3000 index, effective after market close Friday. Shares of Avalo Therapeutics were up more than 1% pre-bell.

$ACAD$AVTX$IBB$INCY$XLV
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks edged lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.3% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped 6%.Cogent Biosciences (COGT) said Bezuclastinib showed "rapid and deep" clinical benefit in advanced systemic mastocytosis patientsfollowing detailed and updated trial results. Shares rose 1.6%.

$AVTX$COGT$JAZZ
Research

BofA Initiates Avalo Therapeutics at Buy With $35 Price Target

Avalo Therapeutics (AVTX) has an average rating of buy and mean price target of $46.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$AVTX
Insider Trading

Avalo Therapeutics Insider Sold Shares Worth $1,513,673, According to a Recent SEC Filing

Paul Varki, Chief Legal Officer, on May 06, 2026, sold 75,063 shares in Avalo Therapeutics (AVTX) for $1,513,673. Following the Form 4 filing with the SEC, Varki has control over a total of 3,634 common shares of the company, with 3,634 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/xslF345X05/form4-05072026_080504.xml

$AVTX
Wire

Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating

Avalo Therapeutics Inc (AVTX) has an average rating of buy and mean price target of $44.40, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $19.53, Change: $+3.27, Percent Change: +20.11%

$AVTX
Wire

Avalo Therapeutics Prices $375 Million Public Offering; Shares Up Pre-Bell

Avalo Therapeutics (AVTX) priced an underwritten public offering of 19.73 million shares at $17.75 each and 1.4 million pre-funded warrants at $17.749 each, for total gross proceeds of about $375 million, the company said Tuesday.The underwriters were granted a 30-day option to purchase up to an additional 3.17 million shares to cover overallotments, the company added.Avalo plans to use the proceeds, alongside existing cash, to advance abdakibart through Phase 3 and for general corporate purposes.The offering is expected to close on Thursday.Shares of the company were up more than 42% in premarket activity Wednesday.Price: $23.21, Change: $+6.95, Percent Change: +42.74%

$AVTX

Track with the FINWIRES app suite

FolioX
FolioX
Track AVTX in your portfolio
WheelAI
WheelAI
Analyze AVTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on AVTX